LifeStance appears to have achieved a structural profitability inflection, with revenue growth accelerating to 26.1% in 2026Q2 alongside a gross margin expansion to 35.2%, driving operating income to $30.7M from a $15.9M loss two years prior. The company's tra...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.06+83.2% vs $0.03 | $435M+5.0% vs $415M |
Q2 2026 May 7, 2026 | $0.04+300.0% vs $0.01 | $404M+4.1% vs $387M |
Q1 2026 Feb 25, 2026 | $0.03 vs -$0.00 | $382M+1.0% vs $378M |
Q4 2025 Nov 6, 2025 | $0.00+127.7% vs -$0.01 | $364M-3.9% vs $379M |
LifeStance Health Group, Inc. (LFST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
LifeStance Health Group (NASDAQ: LFST - Get Free Report) and Mangoceuticals (NASDAQ: MGRX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings. Insider and Institutional Ownership 85.5% of LifeStance Health
Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
Rising oil prices and inflation worries shift the spotlight to five low-leverage stocks, with strong earnings growth & balance sheets.
Benchmark LFST against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for LifeStance Health Group, Inc. (LFST)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.55 | $4.87B | 627.50 | 13.85% | 0.68% | 0.65% | — | |
| $29.37 | $2.73B | -2.42 | 5.04% | -33.44% | -46.01% | — | |
| $179.29 | $10.85B | 7.76 | 9.71% | 8.42% | 20.37% | — | |
| $15.80 | $2.07B | -25.90 | 6.24% | -2.63% | -2.59% | — | |
| $23.90 | $3.75B | 18.82 | 13.03% | 3.68% | 15.83% | — | |
| $176.32 | $10.28B | 30.19 | 18.72% | 6.9% | 16.51% | — |
LifeStance Health Group, Inc. (LFST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
LifeStance Health Group, Inc. (LFST) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 7, 2026·SEC
Jun 4, 2026·SEC
Get notified when LFST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LifeStance Health Group, Inc. (LFST) stock FAQ — growth, dividends, profitability & financials explained
LifeStance Health Group, Inc. (LFST) reported $1.58B in revenue for fiscal year 2025. This represents a 646% increase from $212.5M in 2019.
LifeStance Health Group, Inc. (LFST) grew revenue by 13.9% over the past year. This is steady growth.
Yes, LifeStance Health Group, Inc. (LFST) is profitable, generating $50.6M in net income for fiscal year 2025 (0.7% net margin).
LifeStance Health Group, Inc. (LFST) has a return on equity (ROE) of 0.7%. This is below average, suggesting room for improvement.
LifeStance Health Group, Inc. (LFST) generated $210.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
